Linked Life Data

19556122

Source:http://linkedlifedata.com/resource/pubmed/id/19556122

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2009-9-1
pubmed:abstractText
This study was performed to assess the toxicities, the maximum-tolerated dose (MTD), the pharmacokinetics and the anti-tumour activity of gemcitabine given by 24-h hepatic arterial infusion (HAI).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1879-0852
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2519-27
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion.
pubmed:affiliation
Department of Medical Oncology, VU University Medical Center, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
pubmed:publicationType
Journal Article, Clinical Trial, Phase I